




PHARMACEUTICAL 2021

Unity Biotechnology Inc.
Rank 259 of 402





PHARMACEUTICAL 2021

Unity Biotechnology Inc.
Rank 259 of 402



The relative strengths and weaknesses of Unity Biotechnology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Unity Biotechnology Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 44% points. The greatest weakness of Unity Biotechnology Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 97% points.

The company's Economic Capital Ratio, given in the ranking table, is 42%, being 5.0% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	100,866
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,463
Liabilities, Non-Current	58,976
Other Assets	42,826
Other Compr. Net Income	-85
Other Expenses	3,888
Other Liabilities	0
Other Net Income	1,378
Other Revenues	0
Property and Equipment	12,627
Research and Development	67,309
Selling, General and Administrative Expense	24,025

Output Variable	Value in 1000 USD
Assets	156,319
Liabilities	73,439
Expenses	95,222
Revenues	0
Stockholders Equity	82,880
Net Income	-93,844
Comprehensive Net Income	-93,886
Economic Capital Ratio	42%